adivo

adivo is a biotech company generating therapeutic antibodies for companion animals, addressing the medical needs in dogs, with an upside potential for a future in care for other species.
Antibody selection is based on a novel fully synthetic, dog-specific phage display library that allows de-novo identification of antibodies to select a drug candidate with optimal properties.
adivo is a spin-off from MorphoSys AG, a leading European biopharmaceutical company. The team transfers an in-depth expertise in discovery and development of human therapeutic antibodies to the veterinary market.

Press releases

Press
20. August 2018
Pet therapeutic antibody firm adivo announces closure of seed-financing round
German biotech company adivo specializing in generating species-specific therapeutic antibodies for companion animals announces that it received a seed financing from three investors. The adivo team aims to address high medical needs in dogs including cancer and chronic inflammation, with the potential of expanding activities into the development of therapeutics for other species in the future. “Now, we are very pleased to have gained three strong and reliable partners that share our vision
 

Info & Contact

Kathrin Ladetzki-Baehs
Phone:
+49 (0) 89 588088-471
Markus Waldhuber
Phone:
+49 (0) 89 588088-478
Web:
www.adivo.vet

Address

adivo GmbH
Am Klopferspitz 19
82152 Martinsried/ Planegg

In portfolio

19. Jul 2018

HTGF Manager

 
Dr. Lena Krzyzak, Principal / Authorized Signatory